Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

safety and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... has been extremely challenging because there are many genetic ... cause disease. Now investigators reporting in the July 3rd ... Cell describe a strategy that may help reveal ... factors or environmental exposures to affect the development of ... that may predispose individuals to schizophrenia. , The ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... sunlight at a modest cost is a challenge with ... paper in a special energy issue of Optics ... a relatively new approach to solar cells: lacing them ... the article, this approach has the potential to greatly ...
... GREENBELT, Md. - Engineers at the University of Idaho ... in upcoming NASA missions that will study the Earth ... of a grant technical officer Pen-Shu Yeh, a senior ... the engineering team at the University of ...
... Md. - Engineers at the University of Idaho have ... upcoming NASA missions that will study the Earth and ... a grant technical officer Pen-Shu Yeh, a senior engineer ... engineering team at the University of Idaho,s ...
Cached Biology Technology:Enhancing solar cells with nanoparticles 2New one-of-a-kind technology will fly on 2 NASA missions 2New one-of-a-kind technology will fly on 2 NASA missions 3New one-of-a-kind technology will fly on two NASA missions 2New one-of-a-kind technology will fly on two NASA missions 3
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... varieties with higher yields and enhanced nutritional content, researchers ... with scientists at nine other institutions in an attempt ... endeavor, led by researchers at the U.K.-based Biotechnology and ... in the journal Nature . "This work ...
... release is available in Spanish . WASHINGTON, ... as part of an international team have completed a "shotgun sequencing" ... Nature reported today. The achievement is expected to increase ... wheat varieties with enhanced nutritional value. "By unlocking the ...
... code of one of the world,s most important crops. The ... genome, published today in Nature , is a major ... better able to cope with disease, drought and other stresses ... wheat genes, and insights into the links between them, lays ...
Cached Biology News:UC Davis researchers aid effort to sequence the complex wheat genome 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 3Major breakthrough in deciphering bread wheat's genetic code 2Major breakthrough in deciphering bread wheat's genetic code 3Major breakthrough in deciphering bread wheat's genetic code 4
... The VSOS-4 Orbital Shaker is designed to ... provide a uniform motion that is both mixing ... VSOS-4 Orbital Shaker provides a smooth, quiet, reproducible ... a wide range of laboratory applications such as ...
... Titer Kit is designed for determination of baculovirus ... days as in other methods. Classical determination of ... plaques, but the FastPlax Kit takes advantage of ... glycoprotein on the cell surface as early as ...
... state-of-the-art software for all your biopharmaceutical applications ... a single, scalable software package. The graphical ... the control of all Freedom instruments from ... 100 with one liquid handling arm up ...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
Biology Products: